神经胶质瘤

Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-51.全文  摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].全文

Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021 Mar;18(3):170-86.全文  摘要

Mohile NA, Messersmith H, Gatson NT, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022 Feb 1;40(4):403-26.全文  摘要

Liau LM. Guidelines for newly diagnosed glioblastoma. J Neurooncol. 2008 Sept;89(3).全文

Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016 Apr 7;374(14):1344-55.全文  摘要

American Association of Neurological Surgeons; Congress of Neurological Surgeons. Updated AANS/CNS guidelines for progressive glioblastoma patients. Jun 2022 [internet publication].全文

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-51.全文  摘要

2. Burkhard C, Di Patre PL, Schuler D, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg. 2003 Jun;98(6):1170-4. 摘要

3. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022 Oct 5;24(5 suppl):v1-95.全文  摘要

4. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96.全文  摘要

5. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007 Feb;44(2):81-8.全文  摘要

6. Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021 Oct;123:50-66.全文  摘要

7. Miller JJ, Gonzalez Castro LN, McBrayer S, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 Jan 5;25(1):4-25.全文  摘要

8. World Health Organization. Central nervous system tumours: WHO classification of tumours. 5th ed. vol 6. Lyon, France: IARD Press; 2021.

9. Paulino AC, Mai WY, Chintagumpala M, et al. Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1381-7. 摘要

10. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends and epidemiology. Curr Opin Oncol. 2001 May;13(3):160-6. 摘要

11. Braganza MZ, Kitahara CM, Berrington de González A, et al. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012 Nov;14(11):1316-24.全文  摘要

12. Campian J, Gutmann DH. CNS tumors in neurofibromatosis. J Clin Oncol. 2017 Jul 20;35(21):2378-85.全文  摘要

13. Roth J, Roach ES, Bartels U, et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment - recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 2013 Dec;49(6):439-44.全文  摘要

14. Rocca V, Blandino G, D'Antona L, et al. Li-Fraumeni syndrome: mutation of TP53 is a biomarker of hereditary predisposition to tumor: new insights and advances in the treatment. Cancers (Basel). 2022 Jul 27;14(15):3664.全文  摘要

15. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med. 1995 Mar 30;332(13):839-47.全文  摘要

16. Schüz J, Pirie K, Reeves GK, et al. Cellular telephone use and the risk of brain tumors: update of the UK million women study. J Natl Cancer Inst. 2022 May 9;114(5):704-11.全文  摘要

17. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014 Jul;16(7):896-913.全文  摘要

18. Turner MC. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother. 2012 Sep;61(9):1493-510. 摘要

19. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002 Oct;4(4):278-99.全文  摘要

20. McKinnon C, Nandhabalan M, Murray SA, et al. Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021 Jul 14;374:n1560. 摘要

21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].全文

22. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021 Mar;18(3):170-86.全文  摘要

23. Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2022 Jan 1;128(1):47-58.全文  摘要

24. Rudà R, Capper D, Waldman AD, et al. EANO - EURACAN - SNO guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro Oncol. 2022 Dec 1;24(12):2015-34.全文  摘要

25. Gonzalez Castro LN, Milligan TA. Seizures in patients with cancer. Cancer. 2020 Apr 1;126(7):1379-89.全文  摘要

26. Johnson DR, Glenn CA, Javan R, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults. J Neurooncol. 2022 Jun;158(2):139-65. 摘要

27. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 Aug 17;22(8):1073-113.全文  摘要

28. National Institute for Health and Care Excellence. Brain tumours (primary) and brain metastases in over 16s. Jan 2021 [internet publication].全文

29. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387.全文  摘要

30. Snyder H, Robinson K, Shah D, et al. Signs and symptoms of patients with brain tumors presenting to the emergency department. J Emerg Med. 1993 May-Jun;11(3):253-8. 摘要

31. Alentorn A, Hoang-Xuan K, Mikkelsen T. Presenting signs and symptoms in brain tumors. Handb Clin Neurol. 2016;134:19-26. 摘要

32. DeAngelis LM. Brain tumors. N Engl J Med. 2001 Jan 11;344(2):114-23. 摘要

33. Whittle IR, Pringle AM, Taylor R. Effects of resective surgery for left-sided intracranial tumors on language function: a prospective study. Lancet. 1998 Apr 4;351(9108):1014-8. 摘要

34. Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery. 2007 Nov;61(5):935-48. 摘要

35. Kickingereder P, Andronesi OC. Radiomics, metabolic, and molecular MRI for brain tumors. Semin Neurol. 2018 Feb;38(1):32-40. 摘要

36. Grimstad IA, Hirschberg H, Rootwelt K. 99m Tc-hexamethyl propyleneamine oxime leukocyte scintigraphy and C-reactive protein levels in the differential diagnosis of brain abscess. J Neurosurg. 1992 Nov;77(5):732-6. 摘要

37. Berkman JM, Nakhate V, Gonzalez Castro LN. Glioblastoma in patients with multiple sclerosis. Neurohospitalist. 2022 Oct;12(4):607-16. 摘要

38. Lee YY, Van Tassel P, Bruner JM, et al. Juvenile pilocytic astrocytomas: CT and MR characteristics. AJR Am J Roentgenol. 1989 Jun;152(6):1263-70.全文  摘要

39. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.全文  摘要

40. Stupp R, Brada M, van den Bent MJ, et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(suppl 3):iii93-101.全文  摘要

41. Mohile NA, Messersmith H, Gatson NT, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022 Feb 1;40(4):403-26.全文  摘要

42. Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021 Nov 2;23(11):1835-44.全文  摘要

43. Roth P, Pace A, Le Rhun E, et al. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO clinical practice guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol. 2021 Feb;32(2):171-82.全文  摘要

44. Youssef G, Wen PY. Medical and neurological management of brain tumor complications. Curr Neurol Neurosci Rep. 2021 Sep 20;21(10):53. 摘要

45. Liau LM. Guidelines for newly diagnosed glioblastoma. J Neurooncol. 2008 Sept;89(3).全文

46. Zhang L, Li D, Xiao D, et al. Improving brain health by identifying structure-function relations in patients with neurosurgical disorders. BMJ. 2020 Oct 9;371:m3690.全文  摘要

47. Fountain DM, Bryant A, Barone DG, et al. Intraoperative imaging technology to maximise extent of resection for glioma: a network meta-analysis. Cochrane Database Syst Rev. 2021 Jan 4;1(1):CD013630.全文  摘要

48. Dhawan S, Patil CG, Chen C, et al. Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas. Cochrane Database Syst Rev. 2020 Jan 20;1(1):CD009229.全文  摘要

49. Halasz LM, Attia A, Bradfield L, et al. Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022 Sep-Oct;12(5):370-86.全文  摘要

50. Bell EH, Zhang P, Shaw EG, et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol. 2020 Oct 10;38(29):3407-17.全文  摘要

51. Lawrie TA, Gillespie D, Dowswell T, et al. Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. Cochrane Database Syst Rev. 2019 Aug 5;8(8):CD013047.全文  摘要

52. Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016 Apr 7;374(14):1344-55.全文  摘要

53. van den Bent MJ, Tesileanu CMS, Wick W, et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021 Jun;22(6):813-23.全文  摘要

54. Khan L, Soliman H, Sahgal A, et al. External beam radiation dose escalation for high grade glioma. Cochrane Database Syst Rev. 2020 May 21;5(5):CD011475.全文  摘要

55. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017 Dec 19;318(23):2306-16.全文  摘要

56. Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007294.全文  摘要

57. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pediatric central nervous system cancers [internet publication].全文

58. Patrick HH, Sherman JH, Elder JB, et al. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults. J Neurooncol. 2022 Jun;158(2):167-77. 摘要

59. American Association of Neurological Surgeons; Congress of Neurological Surgeons. Updated AANS/CNS guidelines for progressive glioblastoma patients. Jun 2022 [internet publication].全文

60. Goodman AL, Velázquez Vega JE, Glenn C, et al. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults. J Neurooncol. 2022 Jun;158(2):179-224. 摘要

61. McBain C, Lawrie TA, Rogozińska E, et al. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579.全文  摘要

62. Ziu M, Goyal S, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults. J Neurooncol. 2022 Jun;158(2):255-64. 摘要

63. Germano IM, Ziu M, Wen P, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. J Neurooncol. 2022 Jun;158(2):225-53. 摘要

64. Wang H, Guo J, Wang T, et al. Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis. BMJ Open. 2021 Dec 2;11(12):e048975.全文  摘要

65. Winograd E, Germano I, Wen P, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma. J Neurooncol. 2022 Jun;158(2):265-321.全文  摘要

66. Taylor LP, Besbris JM, Graf WD, et al. Clinical guidance in neuropalliative care: an AAN position statement. Neurology. 2022 Mar 8;98(10):409-16.全文  摘要

67. Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019 Jan;20(1):110-9. 摘要

68. Juric V, Murphy B. Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions. Cancer Drug Resist. 2020;3(1):48-62.全文  摘要

69. Bota DA, Mason W, Kesari S, et al. Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. Neurooncol Adv. 2021 Jan-Dec;3(1):vdab142.全文  摘要

70. ClinicalTrials.gov. Stage 1: marizomib + bevacizumab in WHO Gr IV GBM; Stage 2: marizomib alone; Stage 3: combination of marizomib and bevacizumab. Jun 2022 [internet publication].全文

71. Sim HW, Galanis E, Khasraw M. PARP inhibitors in glioma: a review of therapeutic opportunities. Cancers (Basel). 2022 Feb 16;14(4):1003.全文  摘要

72. Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020 Jul 1;6(7):1003-10.全文  摘要

73. Lee A, Arasaratnam M, Chan DLH, et al. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Database Syst Rev. 2020 May 12;5(5):CD013238.全文  摘要

74. Youssef G, Dietrich J. Ipilimumab: an investigational immunotherapy for glioblastoma. Expert Opin Investig Drugs. 2020 Nov;29(11):1187-93. 摘要

75. Cloughesy TF, Petrecca K, Walbert T, et al. Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA Oncol. 2020 Dec 1;6(12):1939-46.全文  摘要

76. Liau LM, Ashkan K, Brem S, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2022 Nov 17 [Epub ahead of print].全文  摘要

77. Platten M, Bunse L, Wick A, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021 Apr;592(7854):463-8.全文  摘要

78. Maggs L, Cattaneo G, Dal AE, et al. CAR T cell-based immunotherapy for the treatment of glioblastoma. Front Neurosci. 2021 May 25;15:662064.全文  摘要

79. Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022 Mar;603(7903):934-41.全文  摘要

80. Kristeleit R, Evans J, Molife LR, et al. Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. Br J Cancer. 2020 Oct;123(9):1360-9.全文  摘要

81. Ha W, Sevim-Nalkiran H, Zaman AM, et al. Ibudilast sensitizes glioblastoma to temozolomide by targeting macrophage migration Inhibitory Factor (MIF). Sci Rep. 2019 Feb 27;9(1):2905.全文  摘要

82. Dhillon S. Decitabine/cedazuridine: first approval. Drugs. 2020 Sep;80(13):1373-8.全文  摘要

83. Dhillon S. Correction to: Decitabine/cedazuridine: first approval. Drugs. 2021 Jan;81(1):179.全文  摘要

84. Johnson DR, Brown PD, Galanis E, et al. Pilocytic astrocytoma survival in adults: analysis of the surveillance, epidemiology, and end results program of the National Cancer Institute. J Neurooncol. 2012 May;108(1):187-93. 摘要

85. Tabash MA. Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States; SEER-based analysis. J Neurol Sci. 2019 May 15;400:148-52. 摘要

86. von Deimling A, Ono T, Shirahata M, et al. Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing. Semin Neurol. 2018 Feb;38(1):19-23. 摘要

87. Hamilton MG, Hull RD, Pineo GH. Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery. 1994 Feb;34(2):280-96. 摘要

88. Beevers Z, Hussain S, Boele FW, et al. Pharmacological treatment of depression in people with a primary brain tumour. Cochrane Database Syst Rev. 2020 Jul 17;7(7):CD006932.全文  摘要

89. Kirkman MA, Day J, Gehring K, et al. Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. Cochrane Database Syst Rev. 2022 Nov 25;11(11):CD011335.全文  摘要